

CITATION REPORT

List of articles citing

Is the UK NICE "reference case" influencing the practice of pediatric quality-adjusted life-year measurement within economic evaluations?

DOI: 10.1016/j.jval.2014.02.007
Value in Health, 2014, 17, 454-61.

Source: <https://exaly.com/paper-pdf/59614782/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
18	Measuring Health Utilities in Children and Adolescents: A Systematic Review of the Literature. <i>PLoS ONE</i> , 2015 , 10, e0135672	3.7	61
17	A scoping review of pediatric economic evaluation 1980-2014: do trends over time reflect changing priorities in evaluation methods and childhood disease?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016 , 16, 599-607	2.2	5
16	Economic Evaluation of Childhood Obesity Interventions: Reflections and Suggestions. <i>Pharmacoeconomics</i> , 2016 , 34, 733-40	4.4	11
15	The prevalence of child-specific utilities in NICE appraisals for paediatric indications: rise of the economic orphans?. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2016 , 16, 347-50	2.2	7
14	Sources and Characteristics of Utility Weights for Economic Evaluation of Pediatric Vaccines: A Systematic Review. <i>Value in Health</i> , 2016 , 19, 255-66	3.3	11
13	Economic Evaluation of Family-Based Therapies for Children and Adolescents: what do we know?. <i>Global & Regional Health Technology Assessment</i> , 2017 , 4, grhta.5000272	0.2	1
12	Economic impact of screening for X-linked Adrenoleukodystrophy within a newborn blood spot screening programme. <i>Orphanet Journal of Rare Diseases</i> , 2018 , 13, 179	4.2	2
11	Patterns, trends and methodological associations in the measurement and valuation of childhood health utilities. <i>Quality of Life Research</i> , 2019 , 28, 1705-1724	3.7	13
10	Parental Health Spillover in Cost-Effectiveness Analysis: Evidence from Self-Harming Adolescents in England. <i>Pharmacoeconomics</i> , 2019 , 37, 513-530	4.4	11
9	Valuing health for oneself versus one's child or elderly parent. <i>Journal of Health Psychology</i> , 2019 , 24, 1965-1975	3.1	8
8	Cost-Effectiveness of a School-Based Social and Emotional Learning Intervention: Evidence from a Cluster-Randomised Controlled Trial of the Promoting Alternative Thinking Strategies Curriculum. <i>Applied Health Economics and Health Policy</i> , 2020 , 18, 271-285	3.4	6
7	Assessing quality of life in psychosocial and mental health disorders in children: a comprehensive overview and appraisal of generic health related quality of life measures. <i>BMC Pediatrics</i> , 2020 , 20, 329	2.6	3
6	Health utility estimation in children and adolescents: a review of health technology assessments. <i>Current Medical Research and Opinion</i> , 2020 , 36, 1209-1224	2.5	0
5	Health utilities in pediatric cancer patients and survivors: a systematic review and meta-analysis for clinical implementation. <i>Quality of Life Research</i> , 2021 , 1	3.7	2
4	The Challenges of Measuring and Valuing Quality of Life in Preschool Children: A Retrospective Review of NICE Appraisals. <i>Children</i> , 2021 , 8,	2.8	2
3	A randomised placebo-controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study. <i>Health Technology Assessment</i> , 2016 , 20, i-xxiv, 1-84	4.4	17
2	Pressure garment to prevent abnormal scarring after burn injury in adults and children: the PEGASUS feasibility RCT and mixed-methods study. <i>Health Technology Assessment</i> , 2018 , 22, 1-162	4.4	12

- 1 Acceptability of Manufacturer-Proposed Utility Values for NICE Cancer Medicine Appraisals: Analysis of Manufacturers' Information Sources.. *International Journal of Technology Assessment in Health Care*, **2022**, 38, e25 1.8